HEMOPHILIA A

 

·        Hemophilia A (classic hemophilia, factor VIII deficiency hemophilia) is a hereditary disorder in which bleeding is due to deficiency of the coagulation factor VIII

·        X-linked recessive disease, and as a rule only males are affected

·        In rare instances, female carriers are clinically affected if their normal X chromosomes are disproportionately inactivated. Females may also become affected if they are the offspring of a hemophiliac father and carrier mother.

·        Severe if factor VIII:C levels are less than 1%

·        Moderate if levels are 1–5%

·        Mild if levels are greater than 5%.

o       Clinical Findings

·        Hemophilia A is the most common severe bleeding disorder

·        Second most common congenital bleeding disorder ( after vWD)

·        Bleeding may occur anywhere.

·        The most common sites of bleeding are into joints (knees, ankles, elbows), into muscles, and from the gastrointestinal tract.

·        Spontaneous hemarthroses are so characteristic of severe hemophilia that they are almost diagnostic of the disorder.

·        Patients with mild hemophilia bleed only in response to major trauma or surgery.

·        Patients with moderately severe hemophilia bleed in response to mild trauma or surgery, and those with severe hemophilia bleed spontaneously.

o       Laboratory Findings:

·        The partial thromboplastin time (PTT) is prolonged

·        Pothrombin time, bleeding time, and fibrinogen level, are normal.

·        Levels of factor VIII:C are reduced, but measurements of von Willebrand factor are normal

·        A low platelet count should raise a suspicion of HIV-associated immune thrombocytopenia. As HIV has become relative common in the hemophiliacs due to previous infected blood transfusions.

o       Differential Diagnosis

·        The finding of a reduced factor VIII:C level will distinguish this disorder from other causes of prolonged PTT

·        Clinically, factor VIII hemophilia is indistinguishable from factor IX hemophilia ( Hemophilia B)

·        In cases of mild hemophilia, the disorder needs to be distinguished from von Willebrand's disease by VIII:A assay, which shows normal levels of factor VIII antigen in the former.

·        Female carriers can usually be identified by the presence of low or normal levels of factor VIII:C with normal levels of factor VIII antigen.

o       Treatment

·        Lve as nearly normal lives as possible

·        Activities associated with a risk of trauma should be avoided

·        Asprin should never be used.

·        Standard treatment is based on infusion of factor VIII concentrates, now heat-treated to reduce the likelihood of transmission of HIV.

·        Recombinant factor VIII appears safe and effective, though expensive

·        Head injuries (with or without neurologic signs) should be emergently treated as though major bleeding were present.

·        For mild hemophiliacs, desmopressin acetate, may be useful in preparing for minor surgical procedures.

·        Desmopressin acetate causes release of factor VIII:C and will raise the factor VIII:C levels two- to threefold for several hours.

 

 

OTHER CONGENITAL COAGULATION DISORDERS

 

Hemophilia B

Ø           Hemophilia B (Christmas disease, factor IX hemophilia) is a hereditary bleeding disorder due to deficiency of coagulation factor IX.

Ø           Factor IX deficiency is one-seventh as common as factor VIII deficiency hemophilia but is otherwise clinically and genetically identical.

Ø           The PTT is prolonged, and factor IX levels are reduced when measured by specific factor assays. Other laboratory features are the same as for factor VIII hemophilia.

Ø           Factor IX hemophilia is managed with factor IX concentrates.

Ø           Factor VIII concentrates are ineffectual in this type of hemophilia; therefore it is imperative to distinguish between the two.

Ø           Factor IX concentrates contain a number of other proteins, including activated coagulating factors that appear to contribute to a risk of thrombosis with recurrent usage of factor IX concentrates.

Ø           Desmopressin acetate is not useful in this disorder.

 

Factor XI Deficiency

Ø           This disorder is seen primarily among Ashkenazi Jews

Ø           Autosomal recessive.

Ø           The PTT may be markedly prolonged, and specific assays of factor XI will show reduced levels.

Afibrinogenemia

Ø           Fibrinogen is absent

Ø           Both prothrombin time and partial thromboplastin time are markedly prolonged.

Ø           These patients may have a severe bleeding disorder similar to hemophilia. Fibrinogen is replaced with cryoprecipitate.

 

 

COAGULOPATHY OF LIVER DISEASE

 

·        The liver is the site of synthesis of all the coagulation factors except factor VIII.

·        Vitamin K-dependent factors are factors II, VII, IX, X, protein C and S.

·        Other factor synthesized in the liver is factor V

·        Factor VII levels are the first to decline as they have the shortest half life of 6 hours.

·        Conversely, fibrinogen levels are remarkably well conserved.

Other effects of liver disease on coagulation

·        Increased fibrinolysis occurs because the liver synthesizes a2-antiplasmin (the main inhibitor of fibrinolysis), which is responsible for the clearance of plasminogen activator.

·        Biliary tract disease may lead to malabsorption of vitamin K

·        Congestive splenomegaly may produce mild thrombocytopenia.

·        A variety of chronic liver diseases cause abnormal posttranslation modification of fibrinogen with resultant dysfibrinogenemia.

Clinical Findings

Ø           Bleeding at any site.

Ø           Excessive fibrinolysis may lead to oozing at venipuncture sites.

Ø           Marked abnormality in the prothrombin time (PT) than in the partial thromboplastin time (PTT).

Ø           Early in the course of liver disease, only the PT will become affected.

Ø           Fibrinogen levels should be normal, and the thrombin time should be normal unless dysfibrinogenemia is present.

Ø           The platelet count should be normal unless production is suppressed by acute alcohol ingestion or unless hypersplenism is present.

Ø           The peripheral blood smear may show target cells.

 

Hepatic coagulopathy can be distinguished from vitamin K deficiency only by demonstrating the failure of vitamin K to correct the abnormal values.

 

Causes of prolonged PTT only

Congenital factor deficiencies

Contact factors

Factor XII

Factor XI

Factor IX (hemophilia B)

Factor VIII

Hemophilia A

Von Willebrand’s disease

Anticoagulants

Anti-VIII

Lupus

Heparin

 

 

Causes of isolated prolonged PT only

Liver disease

Vitamin K deficiency

Warfarin therapy

Factor VII deficiency

 

Causes of prolonged PTT and PT.

Liver disease

Vitamin K deficiency

Disseminated intravascular coagulation

Heparin

Warfarin

Isolated factor deficiencies (rare): II, V, X, I

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Treatment

ü      Treat the primary disease

ü      Fresh-frozen plasma is the treatment of choice, and volume overload will limit one's ability to maintain hemostatic factor levels.

ü      Factor IX concentrates are contraindicated in liver disease because of their tendency to cause disseminated intravascular coagulation.

ü      If thrombocytopenia is present, platelet transfusion may be of some help, but platelet recovery is usually disappointing because of hypersplenism.

 

 

VITAMIN K DEFICIENCY

 

v     Vitamin K plays a role in coagulation by acting as a cofactor for the posttranslational γ-carboxylation of zymogens II, VII, IX, and X.

v     Vitamin K is supplied in the diet primarily in leafy vegetables and endogenously from synthesis by intestinal bacteria.

v     Factors that contribute to vitamin K deficiency include

v     Poor diet

v     Malabsorption

v     Broad-spectrum antibiotics suppressing colonic flora.

v     A characteristic setting for vitamin K deficiency is a postoperative patient who is not eating and who is receiving antibiotics.

Clinical Findings

v     There are no specific clinical features, and bleeding may occur at any site.

v     PT is prolonged to a greater extent than the PTT

v     With mild vitamin K deficiency only the PT is defective

v     Fibrinogen level, thrombin time, and platelet count are not affected.

Treatment

Subcutaneous  vitamin K, and a single dose of 15 mg will completely correct laboratory abnormalities in 12–24 hours.

1